Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 10/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | XDH | P47989 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CRHBP | P24387 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6069184 | 0.96 | APP (0.40) | CACNA1BAPPMEN1MAPTCRHBP | |
| Hydrochloric Acid SCHEMBL6069646 | 0.95 | APP (0.39) | CACNA1BAPPMEN1MAPTCRHBP | |
| SCHEMBL6069187 | 0.91 | MITF (0.38) | MEN1MAPTCRHBPKMT2ACRHR2 | |
| SCHEMBL6069164 | 0.90 | MITF (0.39) | APPMEN1MAPTCRHBPKMT2A | |
| SCHEMBL6069404 | 0.89 | MAPT (0.46) | MEN1MAPTCRHBPKMT2ACRHR2 | |
| Hydrochloric Acid SCHEMBL6069441 | 0.88 | MAPT (0.39) | MEN1MAPTCRHBPKMT2ACRHR2 | |
| SCHEMBL6069182 | 0.88 | MAPT (0.47) | MEN1MAPTCRHBPKMT2ACRHR2 | |
| SCHEMBL6069588 | 0.87 | MAPT (0.40) | MEN1MAPTKMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL6069765 | 0.86 | MAPT (0.46) | MEN1MAPTCRHBPKMT2ACRHR2 | |
| SCHEMBL6070027 | 0.86 | HDAC1 (0.41) | MEN1MAPTCRHBPKMT2ACRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074243-B2 | N-benzyl-m-phenylenediamine derivatives and dyes containing said compounds | WELLA AG (DE) | 2006-07-11 | — | — | US | claimed |
| EP-1390341-A1 | N-BENZYL-M-PHENYLENEDIAMINE DERIVATIVES AND DYES CONTAINING SAID COMPOUNDS | Wella Aktiengesellschaft (DE) | 2004-02-25 | — | — | EP | claimed |
| WO-2002096854-A1 | N-BENZYL-M-PHENYLENEDIAMINE DERIVATIVES AND DYES CONTAINING SAID COMPOUNDS | WELLA AKTIENGESELLSCHAFT (DE) | 2002-12-05 | — | — | WO | claimed |
| US-7074243-B2 | N-benzyl-m-phenylenediamine derivatives and dyes containing said compounds | WELLA AG (DE) | 2006-07-11 | — | — | US | disclosed |
| EP-1390341-A1 | N-BENZYL-M-PHENYLENEDIAMINE DERIVATIVES AND DYES CONTAINING SAID COMPOUNDS | Wella Aktiengesellschaft (DE) | 2004-02-25 | — | — | EP | disclosed |
| US-20030182735-A1 | N-benzyl-m-phenylenediamine derivatives and dyes containing said compounds | WELLA AKTIENGESELLSCHAFT (DE) | 2003-10-02 | — | — | US | disclosed |
| WO-2002096854-A1 | N-BENZYL-M-PHENYLENEDIAMINE DERIVATIVES AND DYES CONTAINING SAID COMPOUNDS | WELLA AKTIENGESELLSCHAFT (DE) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030182735-A1 | N-benzyl-m-phenylenediamine derivatives and dyes containing said compounds | KRT18, VIM, KPNB1 | CACNA1B 2531/4885APP 1668/4885XDH 2103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.